Allergan (AGN) Tops Q1 EPS by 39c, Offers FY & Q2 Guidance

Allergan (NYSE: AGN) reported Q1 EPS of $3.74, $0.39 better than the analyst estimate of $3.35. Revenue for the quarter came in at $3.67 billion versus the consensus estimate of $3.59 billion.

GUIDANCE:

Allergan sees 2018 EPS of $15.65-$16.25, versus the consensus of $15.65. Allergan sees 2018 revenue of $15.15-15.35 billion, versus the consensus of $15.22 billion.

Allergan sees Q2 2018 EPS of $4.00-$4.20, versus the consensus of $3.94. Allergan sees Q2 2018 revenue of $3.85-4 billion, versus the consensus of $3.84 billion.

For earnings history and earnings-related data on Allergan (AGN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24